Market Overview

UPDATE: Goldman Sachs Raises PT to $6.60 on Boston Scientific Following Q4 Takeaways

Share:
Related BSX
Stocks Hitting 52-Week Highs
Earnings Scheduled For April 27, 2016
Big Cap Stocks Struggle, But A Few Charts Stand Out (Investor's Business Daily)

Goldman Sachs maintained Boston Scientific Corporation (NYSE: BSX) with a Sell rating and raised the price target from $5.20 to $6.60.

Goldman Sachs noted, "Following 4Q12 results, we adjust our 2013-2016E EPS to reflect: (1) increased sales across most businesses, aside from CRM; (2) revised gross margin assumptions; (3) higher operating expenses; (4) higher interest expense; and (5) increased share repurchases. Still, our revised 2013 sales estimate is now at the low end of guidance (-1.6% vs. the guidance midpoint at -0.7%), as we remain cautious on Boston's business exposure and relative share position."

Boston Scientific closed at $7.10 on Tuesday.

Latest Ratings for BSX

DateFirmActionFromTo
Mar 2016NomuraInitiates Coverage onBuy
Feb 2016SunTrust Robinson HumphreyInitiates Coverage onBuy
Nov 2015CitigroupInitiates Coverage onBuy

View More Analyst Ratings for BSX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Analyst Ratings

 

Related Articles (BSX)

View Comments and Join the Discussion!